Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Return on Equity: 2021-2025

Historic Return on Equity for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to -1.04%.

  • Lyell Immunopharma's Return on Equity fell 70.00% to -1.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.04%, marking a year-over-year decrease of 70.00%. This contributed to the annual value of -0.65% for FY2024, which is 34.00% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Return on Equity is -1.04%, which was up 1.98% from -1.06% recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Return on Equity high stood at 0.51% for Q1 2021, and its period low was -1.06% during Q2 2025.
  • For the 3-year period, Lyell Immunopharma's Return on Equity averaged around -0.53%, with its median value being -0.34% (2024).
  • The largest annual percentage gain for Lyell Immunopharma's Return on Equity in the last 5 years was 33bps (2022), contrasted with its biggest fall of 76bps (2022).
  • Lyell Immunopharma's Return on Equity (Quarterly) stood at -0.22% in 2021, then increased by 1bps to -0.22% in 2022, then dropped by 11bps to -0.33% in 2023, then plummeted by 40bps to -0.73% in 2024, then tumbled by 70bps to -1.04% in 2025.
  • Its Return on Equity was -1.04% in Q3 2025, compared to -1.06% in Q2 2025 and -0.94% in Q1 2025.